Catalog |
name |
Description |
price |
R-R-0328 |
PSMA-617 |
PSMA-617/Vipivotide tetraxetan/CAS: 1702967-37-0 is a radiolabeled monoclonal antibody that binds to the tumor antigen prostate specific membrane antigen (PSMA). It has been shown to be an effective treatment for prostate cancer, with clinical studies showing a significant decrease in tumor volume and size. This drug also had a high uptake rate of urea nitrogen into the tumour xenografts, which is indicative of its effectiveness. PSMA-617 is also useful as a diagnostic tool, as it can be used to diagnose solid tumours such as breast cancer and lung cancer. The biological properties of this drug are still unclear, but it has been shown to have anti-tumor effects when used in combination with radiation therapy. |
price> |
R-R-0332 |
tert-Butyl-DCL (PSMA inhibitor) |
Tert-butyl-DCL/CAS:1025796-31-9 is a small molecule inhibitor that targets prostate-specific membrane antigen (PSMA) for potential cancer therapy. PSMA is a cell surface glycoprotein that is highly expressed in prostate cancer cells, making it a promising target for cancer treatment. Tert-butyl-DCL is designed to specifically bind to PSMA and inhibit its activity, which may lead to the suppression of prostate cancer cell growth and proliferation. This inhibitor is currently being studied in preclinical and clinical trials to evaluate its efficacy and safety as a potential treatment for prostate cancer and other PSMA-expressing cancers. |
price> |
R-R-0334 |
DCFPYL |
DCFPYL/CAS: 1423758-00-2/Piflufolastat can be used to prepare DCFPYL F-18. Pyroflofolate F-18. Pyroflofolate F-18 is an 18F labeled diagnostic imaging agent. Pirflulastatin F-18 can be used for positron emission tomography (PET) targeting (PSMA). |
price> |
R-R-0337 |
DUPA(OtBu)-OH |
DUPA(OtBu)-OH/CAS:1026987-94-9 is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer. PSMA has a high affinity for DUPA(Ki = 8 nM). |
price> |
R-R-0338 |
Vipivotide tetraxetan Linker |
Vipivotide tetraxetan Linker/CAS:1703768-74-4 is a useful peptide linker for synthesis of Vipivotide tetraxetan (PSMA-617). Vipivotide tetraxetan (PSMA-617) is a ligand used to synthesize 177Lu-PSMA-617, which is a radioactive molecule for the treatment of prostate cancer. |
price> |
R-R-0359 |
Succinimidyl-Hynic hydrochloride |
Succinimidyl-Hynic hydrochloride is a chemical reagent, a compound with good stability and water solubility. It can serve as a biomarker. The synthesis of Succinimidyl-Hynic hydrochloride is obtained by chemically reacting two compounds, Succinimidyl and Hynic. It has good reactivity and can react with a variety of biological molecules, thereby changing their properties and functions. In addition, Succinimidyl-Hynic hydrochloride also has good water solubility and stability, and can remain stable in aqueous solutions for a long time. |
price> |
R-R-0360 |
Voclosporin |
Voclosporin/CAS.515814-01-4/ISATX247, a structurally similar analogue of cyclosporin A, is a new type of calcineurin inhibitor. It has been modified to increase its activity by 3-4 times and exhibits a dual and synergistic mechanism. This drug works by blocking the expression of IL-2 and T cell-mediated immune response, stabilizing renal podocytes. Compared to cyclosporin, voclosporin has the advantage of having less impact on cholesterol and triglycerides and a lower risk of diabetes. In February 2021, vorcyclosporine was approved by the FDA for use in combination immunosuppressive regimens in adult patients with active, lupus nephritis. |
price> |
R-R-0408 |
Carbetocin CAS 37025-55-1 |
Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS. |
price> |
R-R-0425 |
CTTHWGFTLC, CYCLIC |
CTTHWGFTLC, CYCLIC/CTT, MMP-2/MMP-9 Inhibitor III/CAS 244082-19-7 from ruixi. Disulfide bond is a protein that regulates muscle cell assembly and interactions. Disulfide bonds are formed by the oxidation of two cysteine molecules, which can be found in the extracellular matrix (ECM). The protein is an important regulator of metalloproteinases, which are enzymes that regulate ECM turnover. When disulfide bond lacks, it causes a deficiency in collagen production. Disulfide bond also has interactions with MMP-2, which plays a role in the regulation of arteriosclerosis and genetic disorders such as muscular dystrophy. |
price> |
R-R-0426 |
N-Bromoacetyl--alanine |
N-Bromoacetyl-β-alanine (CAS 89520-11-6)/N-Bromoacetyl--alanine/UUN20116/3-(2-bromoacetamido)propanoic acid is a compound containing a bromide group and a terminal carboxylic acid. The bromide (Br) is a very good leaving group for nucleophilic substitution reactions. The terminal carboxylic acid can be reacted with primary amine groups in the presence of activators (e.g. EDC, or DCC) to form a stable amide bond. |
price> |